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barrier to the “bench-to-bedside” development of oncolytic
viruses (OVs). A contributing factor is the incomplete and
non-transparent reporting of study methodology and design.
Using the NIH Principles and Guidelines for Reporting Pre-
clinical Research, a core set of seven recommendations, we
evaluated the completeness of reporting of preclinical OV
studies. We also developed an evidence map identifying the
current trends in OV research. A systematic search of
MEDLINE and Embase identiﬁed all relevant articles pub-
lished over an 18 month period. We screened 1,554 articles,
and 236 met our a priori-deﬁned inclusion criteria. Adeno-
virus (43%) was the most commonly used viral platform.
Frequently investigated cancers included colorectal (14%),
skin (12%), and breast (11%). Xenograft implantation (61%)
in mice (96%) was the most common animal model. The
use of preclinical reporting guidelines was listed in 0.4% of
articles. Biological and technical replicates were completely
reported in 1% of studies, statistics in 49%, randomization
in 1%, blinding in 2%, sample size estimation in 0%, and in-
clusion/exclusion criteria in 0%. Overall, completeness of re-
porting in the preclinical OV therapy literature is poor.
This may hinder efforts to interpret, replicate, and ultimately
translate promising preclinical OV ﬁndings.Received 25 January 2019; accepted 9 May 2019;
https://doi.org/10.1016/j.omto.2019.05.004.
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Incomplete and non-transparent reporting of animal experiments1
contributes to the irreproducibility of basic science studies.2,3 Such
irreproducibility may help explain high attrition rates in drug devel-
opment.4 To improve the level of reporting rigor and improve repro-
ducibility, the NIH has identiﬁed essential items to be reported for all
preclinical experimental animal research.5 This core set of preclinical
reporting guidelines (NIH-PRG) lists items that should, at a mini-
mum, be included in a preclinical publication.6 To properly evaluate,
interpret, and reproduce an experiment’s ﬁndings, readers need aMolecular Ther
This is an open access article under the CC BY-NC-clear understanding and appreciation for how the experiment was
conceived, executed, and analyzed. This information is necessary to
judge the validity of ﬁndings. Incomplete and poor reporting does
not allow for an accurate appraisal of the experiment’s value, and
important ﬁndings (positive or negative) could be missed. As demon-
strated in clinical research, the quality and rigor of research improves
when the reporting of key methodological items improves.7,8
Cancer immunotherapy is a rapidly growing ﬁeld.9 Oncolytic, or
“cancer-killing,” viruses (OVs) comprise a promising therapeutic
platform that can elicit anti-cancer immune responses.10–13 Despite
the potential beneﬁts of OV therapy and a multitude of preclinical
candidates, it should be noted that there is currently only one OV
approved for human use by the U.S. Food and Drug Administration
and European Medicines Agency (Imlygic for advanced melanoma,
approved in 2015).14 The current state of OV preclinical study design
and reporting is unknown, as is whether this could explain in part the
relatively small number of approved candidates, despite the ﬁrst
reported studies of the modern OV era being published nearly 30
years ago.15
Our primary objectives were to review and assess the rigor in the
design and completeness of reporting of preclinical in vivo OV ther-
apy studies by applying the recommendations of the NIH-PRG.
Furthermore, our study sought to produce an evidence map high-
lighting the recent global state of OV research and identify commonly
studied viruses, cancers, and animal models. To address this, we used
rigorous methods commonly used for systematic reviews, includingapy: Oncolytics Vol. 14 September 2019 ª 2019 The Author(s). 179
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Flow Diagram for Study Selection
Molecular Therapy: Oncolyticsdeveloping an a priori protocol, a systematic search strategy to iden-
tify eligible articles, and screening of articles and extraction of data
performed independently and in duplicate. Our appraisal of basic
experimental design concepts and key reporting elements aims to in-
crease transparency in preclinical OV research and to improve
“bench-to-bedside” translation for OV immunotherapies.
RESULTS
Study Selection
Our search identiﬁed 1,554 records. Title and abstract screening
excluded 1,244 records, with a subsequent full-text screening180 Molecular Therapy: Oncolytics Vol. 14 September 2019excluding an additional 74 records. Study screening and selection
are summarized in Figure 1. Two-hundred thirty-six articles were
included in our review; the full list and individual data of the included
studies can be found on Open Science Framework (OSF; https://osf.
io/j2dwm/).
Epidemiology of Studies
Articles came from 20 different countries, based on the correspond-
ing author’s residency at the time of publication (Figure 2).
Most common were the United States (n = 72, 31%) and China
(n = 63, 27%). The articles were published in 2016 (n = 169,
Figure 2. Country of Publication
Information based on the corresponding author’s residency at the time of the included article publication (image created using Tableau Software, Seattle, WA, USA).
www.moleculartherapy.org72%) and the ﬁrst 6 months of 2017 (n = 67, 28%) in 85 journals.
The three most commonly acknowledged sources of research fund-
ing were government bodies (n = 196, 43%), academic institutions
(n = 107, 24%), and foundations/charities (n = 94, 21%; total sour-
ces of funding N = 455). The most commonly reported outcome
was tumor size/burden (n = 204, 32%), followed by animal survival
(n = 116, 18%), viral infectivity (n = 109, 17%), and host anti-
tumor response (n = 94, 15%; total number of reported outcomes
N = 630). Seventy-six (32%) articles had titles that clearly indicated
that they contained preclinical experiments. The full results
for study design and publication characteristics can be found in
Table S1.
In total, 26 different viral platforms were used. The most common
was adenovirus (n = 104, 43%) followed by vaccinia virus (n = 34,
14%) and herpes simplex virus (n = 27, 11%; N = 241). The viral treat-
ment most commonly used was intratumoral injection (n = 176, 68%)of an actively replicating virus (n = 182, 77%) in a monotherapy
regimen (n = 152, 59%).
Cancerous cell lines from 23 distinct types of tissue were used
(N = 293). The most common were colorectal (n = 42, 14%),
skin (n = 35, 12%), breast (n = 33, 11%), liver (n = 28, 10%), brain
(n = 25, 9%), and lung (n = 25, 9%). This corresponds with the
incidence of these cancers in humans.16 The majority of cancer
models used heterotopic (n = 170, 66%; N = 259), xenograft
(n = 153, 61%; N = 252), and implant (n = 235, 99%; N = 238)
methods.
The animal models were based on four species, with the majority of
experiments using mice (n = 231, 96%; N = 241). In total, 26,044 an-
imals were used; 25,516 of these were mice. Explicit ethics approval
for animal use was referenced in the majority of articles (n = 172,
73%). The housing and handling of animals was described in 104Molecular Therapy: Oncolytics Vol. 14 September 2019 181
Molecular Therapy: Oncolyticsarticles (44%). The full results for viral, cancer, and animal model data
can be found in Table S2.
Assessment of Reporting
Completeness of reporting against each of the seven NIH-PRG do-
mains was assessed. Each section is labeled by the domains it ad-
dresses, and a brief summary of the items recommended by the
NIH-PRG is provided to guide and orient the reader. The full re-
sults for our reporting assessment can be found in Figure 3 and
Table S3.
The Listing of Reporting Guidelines
The use of community-based nomenclature and reporting standards
are encouraged in the NIH-PRG.5 One article (0.4%) listed the use of
reporting guidelines (Animal Research: Reporting In Vivo Experi-
ments [ARRIVE])17 during study design andmanuscript preparation.
Measurement Techniques
Authors are required to report on whether their ﬁndings were sub-
stantiated under a range of conditions (e.g., different viral dosages
and different models).5 This was reported in 225 articles (95%).
Furthermore, the number of subjects used and measurements per-
formed should be sufﬁciently described, such that a distinction be-
tween biological and technical replicates can be made.5 One-hundred
ﬁve articles (44%) reported the number of times a measurement was
repeated for at least one outcome (e.g., tumor size was measured with
calipers three times at each time point). Two articles (1%) reported
the number of times a measurement was repeated for all experimental
outcomes. Similarly, the number of animals used to measure each
outcome was reported in 25 articles (17%).
Statistics and Sample Size Estimation
Statistical tests used, the exact value of n, and deﬁned measures of
central tendency and dispersion must be included.5 Statistical tests
used were listed in 225 (95%) articles, the exact value of n in 148
(63%) articles, and measures of central tendency and dispersion in
203 (86%) and 206 (87%) articles, respectively. All four items were re-
ported on in 116 articles (49%).
To determine an appropriate number of animals, an a priori power
calculation is required.5 The primary outcome, sample size used,
and the rationale for the sample size must be reported.5 A primary
outcome was explicitly stated in 12 articles (5%). A sample size calcu-
lation was listed in 10 articles (4%); of these, 4 articles (2%) included
the method of calculation (e.g., software package). No articles re-
ported all items related to sample size estimation.
Randomization and Blinding
To reduce selection bias, the randomization of animals and the
method of randomization must be reported.5 This is only applicable
when a study includes multiple experimental arms, which occurred in
234 articles (99%). Random group assignment was stated in 103 arti-
cles (44%); of these, the method of randomization (e.g., use of a soft-
ware package) was described in 2 articles (1%).182 Molecular Therapy: Oncolytics Vol. 14 September 2019In addition, to reduce performance and selection bias, the NIH-PRG
recommends that authors report whether experimenters were blinded
to group assignment and outcome assessment, respectively.5 Blinding
of personnel conducting experiments was listed in 7 articles (3%) and
blinding of personnel assessing outcomes was listed in 15 articles
(6%). Complete blinding (i.e., reporting of all items) was listed in 5
articles (2%).
Inclusion and Exclusion Criteria
Criteria for the exclusion of any data (e.g., animals, results) must be
reported to minimize selection bias.5 Furthermore, authors are ex-
pected to include information regarding the total number of animals
originally procured for the study.5 The total number of animals used
was included in 7 articles (3%). The exclusion of any data, or lack
thereof, was listed in 11 articles (5%). To address selective outcome
reporting, the experimental design (as described in the Materials
and Methods section) was compared to the reported results; 228 ar-
ticles (97%) listed all the ﬁndings. Furthermore, the NIH-PRG re-
quires any pilot or preliminary experiments, as well as any null or
negative results to be reported.5 Pilot studies were reported in 27 ar-
ticles (11%). Null or negative results were explicitly described in 96
articles (41%). No articles reported on all of the items recommended
in the inclusion/exclusion criteria domain.
DISCUSSION
This review was a comprehensive appraisal of the recent preclinical
in vivo OV immunotherapy literature. Included studies were pub-
lished in nearly 100 journals and originated from 20 countries.
Twenty-six different viral platforms (and hundreds of genetically
modiﬁed strains) were used. Twenty-three cancer models (and hun-
dreds of cell lines) were investigated.
Our reporting assessment indicated that basic components of exper-
imental design, such as randomization and blinding, as well as key el-
ements of study methodology, such as sample size estimation and a
priori-deﬁned inclusion/exclusion criteria, are poorly reported. Of
the 21 items identiﬁed from the NIH-PRG recommendations, the
vast majority were absent across included studies. The statistics
domain was partially reported, with 49% of studies reporting all items.
Across the other six NIH-PRG domains complete reporting was 2%,
at most. Collectively, these results demonstrate that the quality of re-
porting in the preclinical in vivoOV therapy literature is poor and the
publication of the NIH-PRG has not yet had a substantive inﬂuence.18
Numerous guidelines for thorough in vivo preclinical study design
and reporting exist.19 This includes the extensive ARRIVE preclinical
reporting guidelines that were published in 2010 (and included all el-
ements of the NIH-PRG).17 Those guidelines were endorsed by hun-
dreds of journals (including many in our sample), learned societies,
and funders; however, adherence has been poor.20–22 In response,
the simpliﬁed NIH-PRG were created in order to focus on seven
key items to report; our study demonstrates that adherence to even
these core reporting elements continues to be poor. Several studies
have demonstrated common trends of poor reporting. Similar to
Figure 3. Reporting Assessment Results
Completeness of reporting across all included studies (N = 236) against the deconstructed NIH preclinical reporting guidelines (NIH-PRG) where n is the number of times each
item was reported. Green and red correspond to an item being reported or not reported, respectively.
www.moleculartherapy.org
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Molecular Therapy: Oncolyticsour study, Macleod et al.23 showed that reporting both on randomi-
zation and the method of randomization was quite low (1.8%) in
in vivo studies published by the Nature publication group; interest-
ingly, after mandatory completion of a reporting checklist was insti-
tuted, the rate increased to 11.2% in these journals. In other studies,
randomization was reported between 0% and 16% of included arti-
cles, depending on the journal and topic.20,22 Comparable results
have also been found for blinding, with Macleod et al.23 ﬁnding 4%
of articles in their sample reporting on blinding of either experi-
menter or outcome assessors (which increased to 22.8% after institu-
tion of a mandatory checklist). Baker et al.20 found approximately
20% of journals reported on blinding in their sample of studies. It
is important to note that, even if a study did not employ randomiza-
tion, blinding, sample size calculations, and other factors, the ﬁnal
publication could still easily adhere to the guidelines by transparently
reporting that these methods were not used.
The Importance of Methodological Rigor and Transparent
Reporting
The importance of rigorous study design and transparent reporting
needs to be encouraged. Omission of key concepts in the preclinical
setting has been associated with the exaggeration of effect sizes, type
I (i.e., false positive) and type II (i.e., false negative) errors, and over-
estimation of the potential for successful bench-to-bedside
translation.24–26 Incorporating methodological rigor into study
design and reporting has been shown to reduce bias in the clinical
setting.27–30 Accordingly, many commentators argue that funda-
mental concepts of clinical trial methodology, such as randomiza-
tion and blinding, should be incorporated into preclinical
experiments to increase study validity.31 These practices allow other
researchers to evaluate the risk of bias in study reports: randomiza-
tion addressing selection bias and blinding addressing performance
bias. Within the cancer ﬁeld, the importance of these design ele-
ments and reporting is evidenced by recent preclinical systematic
reviews and meta-analyses of sunitinib32 and sorafenib.33 These
studies suggested that poor design and incomplete reporting of pre-
clinical studies likely contributed to overestimated effect sizes in an-
imal experiments relative to subsequent clinical studies in human
patients. Within this context, our assessment of the OV literature
is an important one that should be considered as efforts to clinically
translate OV therapies continue. Within the present study, impor-
tant methods to reduce bias, such as randomization and blinding
were reported in only a minority of studies. It is unclear whether
these items are not considered and are therefore omitted from study
design or they are performed and simply not reported—a push to-
ward complete reporting would shed light on this.
Strengths and Limitations
The choice of the NIH-PRG for our reporting tool and the method
through which the recommendations were deconstructed and items
operationalized into a checklist are supported by the expertise of
the multidisciplinary research team, including basic scientists, who
performed this study. Portions of this checklist were previously
used bymembers of our group.34 Furthermore, to ensure that the rele-184 Molecular Therapy: Oncolytics Vol. 14 September 2019vant study characteristics were correctly collected, our team included
several OV experts (C.I., J.S.D., R.A., N.E.-S., R.K., and B.A.K.).
Regarding potential limitations, the validity of included studies and
their risk of bias was not evaluated; this limitation reﬂects reporting
being the primary focus of our study. If risk of bias was evaluated,
we would anticipate that most studies would be deemed “unclear
risk of bias” in a majority of domains, due to a lack of reporting.35 Sec-
ond, it is possible that researchers are aware of reporting guidelines
and rigorous study design, but interpreted items differently or simply
did not report measures that were performed. Third, authors from
countries outside of the United States and those who do not receive
funding from the NIH may be unaware of these guidelines. Finally,
a number of articles (n = 29, 12%) were published in Oncotarget, a
journal that was recently delisted in MEDLINE.36 However, when
comparing the level of reporting in Oncotarget to all other articles,
we found no meaningful differences (Table S4).
Future Steps
We believe the impetus for change will need to come through enforce-
ment by external sources, such as funding agencies and journals
(editorial boards, in particular).21,23 Examples include mandatory
checklists at the time of submission37 or requirement that the study
be preregistered38 on an open-source database prior to study
commencement (similar to clinical trials).
Our study demonstrates that researchers as a community are
either not yet aware of reporting guidelines or have not yet appre-
ciated their signiﬁcance. That is, they may be aware of some of
these concepts (e.g., randomization and blinding), but may not
appreciate the consequence that less rigorous design decisions
have on results (e.g., exaggerating effect size). Here, we posit a
few explanations. First, a contributing factor may be the lack of
available formal training opportunities for basic scientists concern-
ing these design and reporting elements. Clear guidelines on how
these methods should be conducted and reported need to be estab-
lished. Nonetheless, even in the absence of implementation of
these methods, authors should be able to report that they were
not used. Second, the impracticality of implementing these mea-
sures in some situations should be considered. For example, a sin-
gle experimenter cannot be blinded to group allocation or it may
be impossible to fully blind experiments (e.g., blinding may not
be possible in animals treated with OVs, as they develop clearly
visible signs associated with the virus). Again, in these situations,
a lack of blinding could still be reported, for transparency. Third,
studies adhering to a more rigorous design may require more re-
sources (e.g., extra personnel to blind appropriately), access to
which may vary widely among research groups and implementa-
tion of which may not be rewarded or compensated for by funding
agencies at present. This, however, still does not interfere with
transparent reporting regarding the application of these design el-
ements. Last, it is possible that the lack of uptake of reporting
guidelines, by other researchers and journal editors discourages
any change of practices common in the laboratory. Without
NIH-PRG Domain Original Recommendation Operationalized Items
Randomization
“Require authors to state 
whether the samples were 
randomized and specify method 
of randomization, at a minimum 
for all animal experiments.”
1. Randomization 
performed
2. Method stated
Figure 4. Constructing the Reporting Checklist
The NIH Preclinical Reporting Guidelines (NIH-PRG) domain of randomization was deconstructed into two unidimensional items, and each was operationalized into a “yes” or
“no” question.
www.moleculartherapy.orgtangible incentives, the time required for researchers to implement
more rigorous study methodologies and fully report studies may
be outweighed by pressures to publish rapidly.
Conclusions
This review is an extensive reporting assessment against an important
set of published guidelines in a growing ﬁeld of cancer research. Given
the critical need for new cancer treatments, efﬁcient allocation of re-
sources, and reproducible experiments, it is crucial that preclinical
in vivo OV research be conducted and reported in a transparent,
methodical, and rigorous way. The items investigated here are funda-
mental to clinical research and have demonstrated beneﬁts in preclin-
ical research. Future work will need to determine how these guidelines
and their underlying principles should be applied to preclinical
research.
MATERIALS AND METHODS
Protocol
Using the Preferred Reporting Items for Systematic Review andMeta-
Analysis Protocol (PRISMA-P) statement39 as a guide, a study proto-
col was constructed and deposited on OSF (OSF; https://osf.io/
j2dwm/).38 During completion of our review, there were no devia-
tions from the protocol. The protocol was publicly posted concurrent
with the commencement of data extraction. Although not a system-
atic review, the PRISMA statement40 was used in the drafting of
this manuscript.
Eligibility Criteria
We included all preclinical in vivo studies that used an OV therapy
(prophylactic or interventional) to treat cancer, published between
January 2016 and June 2017 (18 months). There were no limitations
on viral platform, cancer model, animal model, comparisons, out-
comes, or experimental design. Only original research, in the form
of full-text English publications, was included. Abstracts, letters, re-
views, and commentaries were excluded. Any in vitro, ex vivo, or clin-
ical experiments were excluded.
Search Strategy and Article Screening
In consultation with an information specialist, a systematic search
strategy was developed (OSF; https://osf.io/j2dwm/), and searches
of MEDLINE and Embase were performed. Titles that met our eligi-bility criteria were identiﬁed and uploaded to an audit-ready, cloud-
based software (Distiller SR; Evidence Partners, Ottawa, ON, Can-
ada). Two independent reviewers performed the process of study
selection. Title and abstract screenings were performed indepen-
dently and in duplicate using an accelerated screening method (one
reviewer required to include, two reviewers required to exclude).41
A subsequent full-text screening was performed in duplicate by two
independent reviewers (consensus required to exclude). Any conﬂicts
were resolved through discussion with a third team member.
Data Extraction
Full-text articles which met our inclusion criteria were retrieved and
uploaded to Distiller SR. All extractors (N.L.W., G.J.L., J.L.M., and
I.C.) were afﬁliated with the Ottawa Hospital Research Institute. To
ensure an adequate level of reviewer agreement, all extractors partic-
ipated in a pilot training exercise. Each extractor was provided with a
training document and independently extracted ﬁve articles. Feed-
back from a core group member (M.M.L.) was given, and a further
ﬁve articles were independently extracted. At this point, the training
exercise was completed, as inter-rater agreement met our pre-deﬁned
level of 80%. Two trained members of the extractor team indepen-
dently extracted data from each article in duplicate. Data were
collected concerning common study characteristics (e.g., country of
corresponding author, journal, funding source, virus administered,
cancer studied, and animal model used) and the level of reporting
against the NIH-PRG domains (e.g., randomization and blinding).
Conﬂicts were resolved through consensus discussions between ex-
tractors or with a senior investigator when needed. Online methods
and supplemental information were retrieved whenever referenced.
Reporting Quality Assessment of Included Studies
The NIH-PRG recommendations are grouped into seven domains:
(1) use of community-based reporting standards, (2) distinction be-
tween biological and technical replicates, (3) statistics, (4) sample
size estimation, (5) randomization, (6) blinding, and (7) inclusion/
exclusion criteria.5 Each of these domains contains a multifaceted
recommendation that addresses multiple points. To assess the level
of reporting, each domain was deconstructed into unidimensional
items. These items were operationalized into 21 “yes” or “no” ques-
tions, each addressing a single point. (The full list of questions is con-
tained in our protocol.42) For example, the domain of randomizationMolecular Therapy: Oncolytics Vol. 14 September 2019 185
Molecular Therapy: Oncolyticswas deconstructed into questions regarding whether random group
assignment was reported and whether the method of randomization
was described (Figure 4). All items mentioned in the NIH-PRG were
considered relevant to our reporting assessment. This 21-item check-
list served as our reporting assessment tool.
Data Synthesis
For each item addressed by the NIH-PRG recommendations, the level
of reporting was expressed as the total number of times each item was
reported (n) across all studies (N). This descriptive statistic, frequency
count, is expressed nominally (n out of N) and as a percentage (n/N).
No formal statistical analysis was performed.
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